Vericiguat is suitable for specific cardiovascular disease patients, but strict evaluation of contraindications is required. This drug is mainly used for the treatment of chronic heart failure and has usage restrictions for special populations such as pregnancy and severe liver dysfunction.

1. Indicative population

(1) Chronic heart failure: Suitable for adult patients with reduced ejection fraction and chronic heart failure (NYHAII-IV grade), especially those who have recently experienced worsening heart failure.

(2) Specific cardiovascular status: Should be used in combination with standard heart failure treatment, suitable for individuals with controllable blood pressure (systolic blood pressure ≥ 100mmHg) and who have not used long-acting nitrate drugs.

2. Taboo population

(1) Pregnancy period: Animal studies have shown embryotoxicity, and those who test positive for pregnancy are contraindicated.

(2) Severe liver dysfunction: Child Pugh C grade or baseline transaminase>3 times ULN is contraindicated.

(3) Specific drug combination: Do not use in combination with phosphodiesterase 5 inhibitors (such as sildenafil) or nitrate drugs, as it may cause severe hypotension.

3. Caution should be exercised when using the target audience

(1) Hypotension tendency: Patients with systolic blood pressure<100mm Hg or a history of orthostatic hypotension should be closely monitored.

(2) Moderate to severe liver function impairment: Children Pugh B grade patients need to reduce their dosage by 50%.

(3) End stage renal disease: Due to limited data on dialysis patients, it is recommended to halve the starting dose.

4. Precautions for special populations

(1) Women of childbearing age: Effective contraception is required during treatment and one month after discontinuation of medication.

(2) Breastfeeding period: It is recommended to pause breastfeeding as medication may be secreted into breast milk.

(3) Elderly patients: Blood pressure and renal function changes need to be monitored for those aged 75 and above.

5. Other taboo situations

(1) Allergy history: Do not use for those who are allergic to Viliximab or excipients.

(2) Acute heart failure: In the decompensated phase, use should be considered only after the condition has stabilized.

(3) Severe mitral stenosis: may lead to hemodynamic deterioration.